The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease
|ClinicalTrials.gov Identifier: NCT00829920|
Recruitment Status : Completed
First Posted : January 27, 2009
Last Update Posted : June 25, 2013
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||44 participants|
|Official Title:||The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease|
|Study Start Date :||November 2008|
|Primary Completion Date :||November 2012|
|Study Completion Date :||February 2013|
Patients with muscle invasive or metastatic bladder cancer who will be planning for treatment with surgery or chemotherapy.
- Effect of therapy [ Time Frame: baseline and then every 2 months ]To determine the effect of therapy (cystectomy or chemotherapy) on circulating tumor cell (CTC) levels in bladder cancer patients.
- Presence of baseline CTC [ Time Frame: baseline and then every 2 months ]Assess for the presence of baseline CTC in bladder cancer patients with muscle-invasive or metastatic disease.
- Assessing insulin like growth factor [ Time Frame: baseline and then every 2 months ]Determine the feasibility of assessing insulin like growth factor (IGF) I-R and c-Met by FISH in circulating tumor cells of patients with advanced bladder cancer.
- Correlation between CTC levels and clinical outcome [ Time Frame: baseline and then every 2 months ]Evaluate for any potential correlation between CTC levels and clinical outcome
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00829920
|United States, Colorado|
|University of Colorado Hospital|
|Aurora, Colorado, United States, 80010|
|Principal Investigator:||Thomas W. Flaig, MD||University of Colorado, Denver|